The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladder.
Jonathan Lawrence Wright
No relevant relationships to disclose
Franklin Lee
No relevant relationships to disclose
William Proctor Harris
No relevant relationships to disclose
Heather H. Cheng
No relevant relationships to disclose
Song Zhao
No relevant relationships to disclose
Thomas Champion
No relevant relationships to disclose
John L. Gore
No relevant relationships to disclose
James Dean
No relevant relationships to disclose
James Dean
No relevant relationships to disclose
Michael P Porter
No relevant relationships to disclose
Evan Y. Yu
No relevant relationships to disclose